Cargando…

Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus

BACKGROUND: In a prospective observational study, we investigated whether patients with active systemic lupus erythematosus (SLE) had higher indices of endothelial damage and dysfunction than healthy controls and whether improved disease control was associated with improvement in these indices. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Parker, Ben, Al-Husain, Awal, Pemberton, Philip, Yates, Allen P, Ho, Pauline, Gorodkin, Rachel, Teh, Lee Suan, Alexander, M Yvonne, Bruce, Ian N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033120/
https://www.ncbi.nlm.nih.gov/pubmed/23644670
http://dx.doi.org/10.1136/annrheumdis-2012-203028
_version_ 1782317766934528000
author Parker, Ben
Al-Husain, Awal
Pemberton, Philip
Yates, Allen P
Ho, Pauline
Gorodkin, Rachel
Teh, Lee Suan
Alexander, M Yvonne
Bruce, Ian N
author_facet Parker, Ben
Al-Husain, Awal
Pemberton, Philip
Yates, Allen P
Ho, Pauline
Gorodkin, Rachel
Teh, Lee Suan
Alexander, M Yvonne
Bruce, Ian N
author_sort Parker, Ben
collection PubMed
description BACKGROUND: In a prospective observational study, we investigated whether patients with active systemic lupus erythematosus (SLE) had higher indices of endothelial damage and dysfunction than healthy controls and whether improved disease control was associated with improvement in these indices. METHODS: Twenty-seven patients with active SLE (four or more American College of Rheumatology (ACR) criteria) and 22 age-matched controls were assessed. Endothelial microparticles (EMPs; CD31+/annexin V+/CD42b−) were quantified using flow cytometry. Brachial artery flow-mediated dilatation (FMD) was measured using automated edge-tracking software. Twenty-two patients had a second assessment at a median (IQR) of 20 (16, 22) weeks after initiating new immunosuppressive therapy. RESULTS: SLE patients had a median (IQR) baseline global British Isles Lupus Assessment Group Disease Activity Index (BILAG-2004) score of 14 (12, 22). CD31+/annexin V+/CD42b− EMPs were higher (157 548/ml (59 906, 272 643) vs 41 025(30 179, 98 082); p=0.003) and endothelial-dependent FMD was lower (1.63% (−1.22, 5.32) vs 5.40% (3.02, 8.57); p=0.05) in SLE patients than controls. CD31+/annexin V+/CD42b− EMPs correlated inversely with FMD (%) (r(2) −0.40; p=0.006). At follow-up, the median (IQR) change in global BILAG-2004 score was −11 (−18, −3). CD31+/annexin V+/CD42b− EMP levels were reduced (166 982/ml (59 906, 278 775 vs 55 655(29 475, 188 659; p=0.02) and FMD had improved (0.33% (−2.31, 4.1) vs 3.19% (0.98, 5.09); p=0.1) at the second visit. CONCLUSIONS: Active SLE is associated with evidence of increased endothelial damage and endothelial dysfunction, which improved with suppression of inflammation. Better control of active inflammatory disease may contribute to improved cardiovascular risk in patients with SLE.
format Online
Article
Text
id pubmed-4033120
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-40331202014-06-05 Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus Parker, Ben Al-Husain, Awal Pemberton, Philip Yates, Allen P Ho, Pauline Gorodkin, Rachel Teh, Lee Suan Alexander, M Yvonne Bruce, Ian N Ann Rheum Dis Clinical and Epidemiological Research BACKGROUND: In a prospective observational study, we investigated whether patients with active systemic lupus erythematosus (SLE) had higher indices of endothelial damage and dysfunction than healthy controls and whether improved disease control was associated with improvement in these indices. METHODS: Twenty-seven patients with active SLE (four or more American College of Rheumatology (ACR) criteria) and 22 age-matched controls were assessed. Endothelial microparticles (EMPs; CD31+/annexin V+/CD42b−) were quantified using flow cytometry. Brachial artery flow-mediated dilatation (FMD) was measured using automated edge-tracking software. Twenty-two patients had a second assessment at a median (IQR) of 20 (16, 22) weeks after initiating new immunosuppressive therapy. RESULTS: SLE patients had a median (IQR) baseline global British Isles Lupus Assessment Group Disease Activity Index (BILAG-2004) score of 14 (12, 22). CD31+/annexin V+/CD42b− EMPs were higher (157 548/ml (59 906, 272 643) vs 41 025(30 179, 98 082); p=0.003) and endothelial-dependent FMD was lower (1.63% (−1.22, 5.32) vs 5.40% (3.02, 8.57); p=0.05) in SLE patients than controls. CD31+/annexin V+/CD42b− EMPs correlated inversely with FMD (%) (r(2) −0.40; p=0.006). At follow-up, the median (IQR) change in global BILAG-2004 score was −11 (−18, −3). CD31+/annexin V+/CD42b− EMP levels were reduced (166 982/ml (59 906, 278 775 vs 55 655(29 475, 188 659; p=0.02) and FMD had improved (0.33% (−2.31, 4.1) vs 3.19% (0.98, 5.09); p=0.1) at the second visit. CONCLUSIONS: Active SLE is associated with evidence of increased endothelial damage and endothelial dysfunction, which improved with suppression of inflammation. Better control of active inflammatory disease may contribute to improved cardiovascular risk in patients with SLE. BMJ Publishing Group 2014-06 2013-05-05 /pmc/articles/PMC4033120/ /pubmed/23644670 http://dx.doi.org/10.1136/annrheumdis-2012-203028 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Clinical and Epidemiological Research
Parker, Ben
Al-Husain, Awal
Pemberton, Philip
Yates, Allen P
Ho, Pauline
Gorodkin, Rachel
Teh, Lee Suan
Alexander, M Yvonne
Bruce, Ian N
Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus
title Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus
title_full Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus
title_fullStr Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus
title_full_unstemmed Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus
title_short Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus
title_sort suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus
topic Clinical and Epidemiological Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033120/
https://www.ncbi.nlm.nih.gov/pubmed/23644670
http://dx.doi.org/10.1136/annrheumdis-2012-203028
work_keys_str_mv AT parkerben suppressionofinflammationreducesendothelialmicroparticlesinactivesystemiclupuserythematosus
AT alhusainawal suppressionofinflammationreducesendothelialmicroparticlesinactivesystemiclupuserythematosus
AT pembertonphilip suppressionofinflammationreducesendothelialmicroparticlesinactivesystemiclupuserythematosus
AT yatesallenp suppressionofinflammationreducesendothelialmicroparticlesinactivesystemiclupuserythematosus
AT hopauline suppressionofinflammationreducesendothelialmicroparticlesinactivesystemiclupuserythematosus
AT gorodkinrachel suppressionofinflammationreducesendothelialmicroparticlesinactivesystemiclupuserythematosus
AT tehleesuan suppressionofinflammationreducesendothelialmicroparticlesinactivesystemiclupuserythematosus
AT alexandermyvonne suppressionofinflammationreducesendothelialmicroparticlesinactivesystemiclupuserythematosus
AT bruceiann suppressionofinflammationreducesendothelialmicroparticlesinactivesystemiclupuserythematosus